Indivior Proposes New Corporate Structure to Achieve U.S. Domiciliation

Core Viewpoint - Indivior PLC plans to change its domicile from the U.K. to the U.S. by establishing a new parent company, Indivior Pharmaceuticals, Inc. (IPI), to leverage the benefits of its U.S. stock listing [1][2]. Group 1: Redomiciliation Process - The redomiciliation will be executed through a U.K. court-sanctioned scheme of arrangement, requiring shareholder approval [2][3]. - Upon approval, Indivior PLC will become a wholly owned subsidiary of IPI, with IPI's common stock listed on Nasdaq under the symbol INDV [2][3]. - Shareholders will receive one IPI share for each Indivior PLC share held, with Indivior PLC shares cancelled at the time of exchange [2]. Group 2: Timeline and Voting - A formal vote by Indivior PLC shareholders is necessary, requiring a majority in number and 75% in value of shares voted [3]. - Key dates include: - Mid November 2025: Issuance of shareholder circular and notice of extraordinary general meeting (EGM) - Early December 2025: EGM held in London - Late January 2026: Effective date of the scheme and trading of IPI shares on Nasdaq begins [7]. Group 3: Strategic Benefits - The change aims to expand Indivior's presence in U.S. capital markets and increase potential U.S. equity indexation [6]. - It will simplify corporate governance and reduce complexity, positioning Indivior as a U.S.-based treatment innovator [6]. - The move is expected to enhance collaboration with public health leaders on advancing SUBLOCADE® for opioid use disorder [6].